Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab ravtansine in advanced solid cancers with hepatic or renal impairment
NCT02696642Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2016
- Primary completion
- Jul 2018
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of anetumab ravtansine in solid tumor (4 arms), sponsored by Bayer. Primary endpoints: Treatment-emergent adverse events, Area Under the Curve and 1 more. Started Apr 2016; status: completed.
02
Drugs
anetumab ravtansine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02696642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696642.